Outcomes of Intravitreal Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration in Kazakhstan

Marat Suleimenov, Baurzhan Kadyrgaliyev, Elmira Kanafyanova, Zhanar Meyermanova, Venera Abdullina, Zulfiya Meirkhanovna Zhankalova, Ainur Yeshmanova, Akmaral B. Abdykulova, Svetlana Almukhambetova, Mukhit Kulmaganbetov

Vision, 2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.3390/vision10040082
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss among older adults. Although randomised controlled trials have demonstrated the robust efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, real-world outcomes often differ markedly from trial findings. This study aimed to evaluate the anatomical and functional outcomes of anti-VEGF therapy in a clinical cohort of nAMD patients, including a subgroup that received adjunctive rescue photodynamic therapy (PDT) with verteporfin. Methods: This single-centre, retrospective observational cohort study included 568 patients (634 eyes) with nAMD treated with intravitreal anti-VEGF injections. Bevacizumab was used in 49% of eyes, ranibizumab in 44%, and aflibercept in 7%. Best recorded visual acuity (BRVA) and central retinal thickness (CRT) measured by optical coherence tomography (OCT) were recorded at baseline and at the final documented follow-up. Eyes with eccentric fixation were excluded from BRVA analysis but were retained for CRT analysis. Results: Mean patient age was 71.7 ± 8.8 years, and 67.6% of eyes were from female patients. The mean number of anti-VEGF injections was 5 ± 5.3 per eye; the mean follow-up duration was 11.5 months. Mean CRT decreased significantly from 347.3 ± 27.5 μm at baseline to 324.9 ± 28.8 μm at final follow-up (p < 0.001). Mean BRVA (logMAR) improved modestly from 0.98 ± 0.55 (Snellen ~20/190; ~35 ETDRS letters) to 0.93 ± 0.56 (Snellen ~20/175; ~37.5 ETDRS letters) (p < 0.001), with 67.9% of eyes demonstrating BRVA stability (change < 0.1 logMAR). Rescue PDT was administered in 10.3% of eyes. Conclusions: In this real-world cohort, anti-VEGF therapy was associated with significant anatomical improvement, as measured by CRT reduction, while functional outcomes were characterised by visual stabilisation rather than substantial gains.